Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
3 studies found for:    pediatric neurofibromatosis brain tumor
Show Display Options
Rank Status Study
1 Active, not recruiting NF1 Brain Tumor Genetic Risk
Conditions: Neurofibromatosis Type 1;   Pediatric Brain Tumor
Intervention:
2 Recruiting Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Conditions: Childhood Cerebellar Astrocytoma;   Childhood Cerebral Astrocytoma;   Childhood Mixed Glioma;   Childhood Pilocytic Astrocytoma;   Neurofibromatosis Type 1;   Recurrent Childhood Anaplastic Oligodendroglioma;   Recurrent Childhood Brain Stem Glioma;   Recurrent Childhood Cerebellar Astrocytoma;   Recurrent Childhood Cerebral Astrocytoma;   Recurrent Childhood Oligodendroglioma;   Recurrent Childhood Pilocytic Astrocytoma;   Recurrent Childhood Visual Pathway Glioma
Interventions: Drug: Selumetinib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
3 Unknown  Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors
Conditions: Neurofibromatosis 2;   Vestibular Schwannoma
Intervention: Drug: Lapatinib

Indicates status has not been verified in more than two years